Unknown

Dataset Information

0

Oncoprotein HBXIP induces PKM2 via transcription factor E2F1 to promote cell proliferation in ER-positive breast cancer.


ABSTRACT: We have reported that hepatitis B X-interacting protein (HBXIP, also termed LAMTOR5) can act as an oncogenic transcriptional co-activator to modulate gene expression, promoting breast cancer development. Pyruvate kinase muscle isozyme M2 (PKM2), encoded by PKM gene, has emerged as a key oncoprotein in breast cancer. Yet, the regulatory mechanism of PKM2 is still unexplored. Here, we report that HBXIP can upregulate PKM2 to accelerate proliferation of estrogen receptor positive (ER+) breast cancer. Immunohistochemistry analysis using breast cancer tissue microarray uncovered a positive association between the expression of HBXIP and PKM2. We also discovered that PKM2 expression was positively related with HBXIP expression in clinical breast cancer patients by real-time PCR assay. Interestingly, in ER+ breast cancer cells, HBXIP was capable of upregulating PKM2 expression at mRNA and protein levels in a dose-dependent manner, as well as increasing the activity of PKM promoter. Mechanistically, HBXIP could stimulate PKM promoter through binding to the -779/-579 promoter region involving co-activation of E2F transcription factor 1 (E2F1). In function, cell viability, EdU, colony formation, and xenograft tumor growth assays showed that HBXIP contributed to accelerating cell proliferation through PKM2 in ER+ breast cancer. Collectively, we conclude that HBXIP induces PKM2 through transcription factor E2F1 to facilitate ER+ breast cancer cell proliferation. We provide new evidence for the mechanism of transcription regulation of PKM2 in promotion of breast cancer progression.

SUBMITTER: Liu BW 

PROVIDER: S-EPMC6462016 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Oncoprotein HBXIP induces PKM2 via transcription factor E2F1 to promote cell proliferation in ER-positive breast cancer.

Liu Bo-Wen BW   Wang Tian-Jiao TJ   Li Lei-Lei LL   Zhang Lu L   Liu Yun-Xia YX   Feng Jin-Yan JY   Wu Yue Y   Xu Fei-Fei FF   Zhang Quan-Sheng QS   Bao Ming-Zhu MZ   Zhang Wei-Ying WY   Ye Li-Hong LH  

Acta pharmacologica Sinica 20180620 4


We have reported that hepatitis B X-interacting protein (HBXIP, also termed LAMTOR5) can act as an oncogenic transcriptional co-activator to modulate gene expression, promoting breast cancer development. Pyruvate kinase muscle isozyme M2 (PKM2), encoded by PKM gene, has emerged as a key oncoprotein in breast cancer. Yet, the regulatory mechanism of PKM2 is still unexplored. Here, we report that HBXIP can upregulate PKM2 to accelerate proliferation of estrogen receptor positive (ER+) breast cance  ...[more]

Similar Datasets

| S-EPMC3616668 | biostudies-literature
| S-EPMC4993364 | biostudies-literature
| S-EPMC7136616 | biostudies-literature
| S-EPMC3898818 | biostudies-literature
| S-EPMC8285905 | biostudies-literature
| S-EPMC8001101 | biostudies-literature
| S-EPMC10949426 | biostudies-literature
| S-EPMC6201343 | biostudies-literature
| S-EPMC9479206 | biostudies-literature
| S-EPMC9617565 | biostudies-literature